Roberts, Glore & Co’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,317
Closed -$222K – 250
2026
Q2
$222K Buy
+1,317
New +$195K 0.05% 228
2026
Q1
– Sell
-1,492
Closed -$212K – 231
2025
Q4
$212K Hold
1,492
– – 0.06% 211
2025
Q3
$209K Buy
+1,492
New +$202K 0.06% 210
2025
Q1
– Sell
-1,492
Closed -$204K – 209
2024
Q4
$204K Buy
+1,492
New +$185K 0.06% 203
2024
Q3
– Sell
-1,492
Closed -$205K – 212
2024
Q2
$205K Hold
1,492
– – 0.06% 197
2024
Q1
$206K Buy
+1,492
New +$204K 0.06% 201

Other funds holding NBIX

Roberts, Glore & Co's NBIX Position: Q3 2026 in Review

Roberts, Glore & Co sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 1,317 shares — an estimated $222K sold.

Roberts, Glore & Co first reported a position in NBIX in Q1 2024 and held it in 6 quarters. The position peaked at $222K in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Roberts, Glore & Co reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
  • Roberts, Glore & Co sold 1,317 Neurocrine Biosciences shares in Q3 2026, an estimated $222K.
  • Roberts, Glore & Co first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 6 quarters.
  • Roberts, Glore & Co's Neurocrine Biosciences position peaked at $222K in Q2 2026.
  • 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Roberts, Glore & Co's 13F filing for Q3 2026, filed 13 Nov 2026.